| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7709517 | ASTELLAS | Diarylhydantoin compounds |
Aug, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126941 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
May, 2026
(2 years from now) | |
| US8183274 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
Aug, 2026
(2 years from now) | |
Xtandi is owned by Astellas.
Xtandi contains Enzalutamide.
Xtandi has a total of 3 drug patents out of which 0 drug patents have expired.
Xtandi was authorised for market use on 31 August, 2012.
Xtandi is available in capsule;oral dosage forms.
Xtandi can be used as treatment of patients with castration-resistant prostate cancer (crpc); the treatment of patients with metastatic castration-sensitive prostate cancer, the treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc).
The generics of Xtandi are possible to be released after 13 August, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 16, 2022 |
Drugs and Companies using ENZALUTAMIDE ingredient
Market Authorisation Date: 31 August, 2012
Treatment: The treatment of patients with metastatic castration-sensitive prostate cancer; Treatment of patients with castration-resistant prostate cancer (crpc)
Dosage: CAPSULE;ORAL
XTANDI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic